B+
Bull case
25%
Probability
Target price
$7.00
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
NUVB
Nuvation BioDNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$5.20
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$2.60
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-25
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+66.4
Score
AI commentary
The deterministic prior is positive with strong primary-source support, but low coverage and limited forward estimates favor a cautious monitoring view. The October 23 anchor is $4.57. No reliable post-update analyst revisions, consensus surprise, options skew, short-interest or social-sentiment measurements were supplied; the zero sentiment fields denote unavailable data, not neutral readings. No cause is assigned to the recent share-price decline.
RankAlpha Sentiment Codex - 2026-10-25
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-10-26eventIBTROZI subgroup data at ESMOMedium impact
Nuvation has scheduled an October 26 presentation of updated efficacy and safety data in ROS1-positive lung-cancer patients previously treated with entrectinib. This may clarify IBTROZI's competitive position, but it is a subgroup analysis, not a new pivotal readout. [#PR-2026-08-04] Company announcement.
2026-11-04eventThird-quarter IBTROZI commercial resultsHigh impact
Nuvation will report third-quarter results and provide a business update on November 4. The decision-relevant test is whether IBTROZI product revenue and first-line patient starts sustain the second-quarter trajectory: $23.2 million in product revenue, up 25% sequentially, and roughly 85% of approximately 160 new starts in TKI-naïve patients. No third-quarter result or consensus estimate is yet available in the packet. [#8-K-2026-08-06] [#SEC-8K-2026-08-06] [#PR-EARNINGS-2026-10-21] SEC earnings exhibit; company announcement.
2027-12-31catalystSafusidenib trial enrollment and development progressHigh impact
Nuvation is enrolling the Phase 3 SIGMA study and pursuing the G307 and post-vorasidenib G209 studies in IDH1-mutant glioma. Progress could broaden the pipeline case, but early Phase 2 findings and Fast Track designation do not establish pivotal efficacy or approval. The date is a monitoring horizon, not a company-promised readout. [#SEC-8K-2026-08-06] Company update.
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-25 • Updated nightlySource: Internal modelMethodology